Cullinan Therapeutics’ (CGEM) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Cullinan Therapeutics (NASDAQ:CGEM) in a research note released on Friday,Benzinga reports. The brokerage currently has a $40.00 price target on the stock.

A number of other research analysts also recently issued reports on CGEM. Wedbush boosted their price target on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. HC Wainwright raised their price objective on shares of Cullinan Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. TD Cowen upgraded shares of Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.71.

Cullinan Therapeutics Stock Performance

Shares of CGEM opened at $14.81 on Friday. The business’s 50-day moving average is $19.77 and its two-hundred day moving average is $16.71. The company has a market capitalization of $953.17 million, a P/E ratio of -4.78 and a beta of 0.02. Cullinan Therapeutics has a fifty-two week low of $5.68 and a fifty-two week high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). Analysts forecast that Cullinan Therapeutics will post -3.08 EPS for the current year.

Insider Buying and Selling

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total value of $172,560.00. Following the sale, the insider directly owned 158,844 shares of the company’s stock, valued at approximately $3,426,265.08. This trade represents a 4.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 46,000 shares of company stock valued at $922,920 over the last quarter. 8.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CGEM. BlackRock Inc. acquired a new stake in Cullinan Therapeutics in the 2nd quarter valued at $95,289,000. Blue Owl Capital Holdings LP purchased a new position in Cullinan Therapeutics during the second quarter valued at $28,039,000. Boothbay Fund Management LLC purchased a new position in Cullinan Therapeutics during the fourth quarter valued at $12,803,000. Dimensional Fund Advisors LP grew its position in shares of Cullinan Therapeutics by 6.7% in the first quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock valued at $12,870,000 after purchasing an additional 57,259 shares during the period. Finally, Boone Capital Management LLC acquired a new stake in shares of Cullinan Therapeutics in the second quarter valued at about $12,828,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Key Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: BTIG reaffirms a Buy rating and $40 price target. The target implies substantial upside from the recent trading level and indicates that BTIG continues to see significant value in Cullinan’s pipeline. Benzinga analyst rating report
• Positive Sentiment: Multiple clinical readouts are scheduled for the fourth quarter. Cullinan expects multi-dose velinotamig data in systemic lupus erythematosus at the ACR Convergence conference in November, followed by CLN-978 data in lupus, rheumatoid arthritis and Sjögren’s disease, plus updated CLN-049 data in December. These updates could provide important evidence for the company’s T-cell engager strategy. Cullinan fourth-quarter 2026 milestones
• Neutral Sentiment: Reported short interest was effectively zero. Data as of September 24 showed no reported shares sold short and a zero-day short-interest ratio, suggesting that short selling is not a clear explanation for the recent weakness. The figures may also reflect a reporting anomaly and should be interpreted cautiously.
• Negative Sentiment: Cullinan delayed early-stage arthritis-therapy data until December. The postponement removes a near-term catalyst and appears to have disappointed investors, increasing focus on execution and the timing of the company’s immunology programs. Cullinan delays arthritis-therapy data
• Negative Sentiment: Zipalertinib sentiment remains unsettled. Although Phase 3 lung-cancer results were characterized as strong, investors continue to question the drug’s safety profile and the durability of the bull case. Those concerns have overshadowed the efficacy data and contributed to selling pressure. CGEM stock and zipalertinib safety concerns

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.